PIK3CG and Burkitt lymphoma: The results showed that PI3KD-IN-015 potently inhibited the phosphorylation of Akt at both Thr308 and Ser473 sites, the downstream target of PI3K, among MOLM-13 (AML), HT (B-NHL), Namalwa (Burkitt Lymphoma), MEC-1 (CLL), MEC-2 (CLL), and HS505T (CLL) cells, with EC50 less than 1 μM (Figure 3).